Drug Profile
Research programme: glucagon receptor antagonists - Ligand Pharmaceuticals
Alternative Names: Cmpd G; Cmpd H; Compound G; Compound HLatest Information Update: 13 Mar 2018
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 12 Mar 2018 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 29 Jan 2010 Ligand Pharmaceuticals acquires Metabasis Therapeutics
- 01 Sep 2008 Pharmacodynamic data from a preclinical trial in Type-2 diabetes presented at the 44th Annual Meeting of European Association for the Study of Diabetes (EASD-2008)